Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
O414289-5mg | 5mg | In stock | $206.90 | |
O414289-10mg | 10mg | In stock | $335.90 | |
O414289-25mg | 25mg | In stock | $612.90 | |
O414289-50mg | 50mg | In stock | $939.90 | |
O414289-100mg | 100mg | In stock | $1,484.90 |
Dehydrogenase Inhibitors
Synonyms | D87221 | 0T4IMT8S5Z | FT-2102FT-2102 | AC-36556 | UNII-0T4IMT8S5Z | 5-[[(1S)-1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | MFCD00211233 | 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydr |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H, IDH1-R132C, respectively. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor |
Product Description | Information Olutasidenib (FT-2102) Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H , IDH1-R132C , respectively. Targets IDH1 (R132H) (Cell-free assay); IDH1 (R132C) (Cell-free assay) 21.1 nM; 114 nM In vitro Profiling in various mIDH1 over-expressing U87 cells and HCT116 cells reveals that olutasidenib potently inhibits 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), suggesting olutasidenib could be efficacious against most IDH1-R132 mutant-expressing tumors. Olutasidenib is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 and IDH2 mutants.. In vivo In IDH1-R132H/ xenograft models, the free concentration of Olutasidenib is comparable in plasma and xenograft tumors, and exposures are dose-dependent. In comparison to the vehicle treated group, Olutasidenib shows a time and dose-dependent inhibition of 2-HG levels in tumor. Calculations based upon the percentage of suppression of 2-HG concentration in tumor versus the free drug concentration in tumor give in vivo IC50 values of 26 nM and 36 nM in the HCT116-IDH1-R132H or HCT116-IDH1-R132C models, respectively. Olutasidenib has good cell permeability and low efflux ratio in the male CD-1 mouse, which indicate a low probability of p-glycoprotein driven efflux.. Cell Research(from reference) Cell lines:HCT116-IDH1-R132H/+, HCT116-IDH1-R132C/+, HT1080, U87MG cells Incubation Time:24 h |
ALogP | 1.234 |
---|---|
HBD Count | 2 |
Rotatable Bond | 3 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile |
---|---|
INCHI | InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 |
InChi Key | NEQYWYXGTJDAKR-JTQLQIEISA-N |
Canonical SMILES | CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N |
Isomeric SMILES | C[C@@H](C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N |
PubChem CID | 118955396 |
Molecular Weight | 354.79 |
PubChem CID | 118955396 |
---|---|
CAS Registry No. | 1887014-12-1 |
RCSB PDB Ligand | PWV |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2208118 | Certificate of Analysis | Jul 04, 2022 | O414289 |
I2208119 | Certificate of Analysis | Jul 04, 2022 | O414289 |
I2208120 | Certificate of Analysis | Jul 04, 2022 | O414289 |
I2208121 | Certificate of Analysis | Jul 04, 2022 | O414289 |
I2208122 | Certificate of Analysis | Jul 04, 2022 | O414289 |
L2412241 | Certificate of Analysis | Jul 04, 2022 | O414289 |
Solubility | Solubility (25°C) In vitro DMSO: 71 mg/mL (200.11 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 71 |
DMSO(mM) Max Solubility | 200.118379886694 |
Water(mg / mL) Max Solubility | <1 |
1. Wang G, Sai K, Gong F, Yang Q, Chen F, Lin J. (2014) Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.. Mol Med Rep, 9 (5): (1799-805). [PMID:24626950] [10.1021/op500134e] |
2. Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D et al.. (2020) Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.. J Med Chem, 63 (4): (1612-1623). [PMID:31971798] [10.1021/op500134e] |